Singer Jesy Nelson recently shared an emotional update regarding the complications she is experiencing in her pregnancy with twin babies. Former Little Mix singer Jesy, who is having twins with partner Zion Foster, announced that she has been diagnosed with pre-twin-to-twin transfusion syndrome (pre-TTTS). The condition, which is present in pregnancies involving twins with a shared placenta, has serious risks involved and needs intense medical supervision. As Nelson embarks on this difficult journey, her story enlightens us about a rare but dangerous condition many expectant parents may not know much about.

Twin-to-twin transfusion syndrome is a rare but dangerous condition that arises in monochorionic twin pregnancies, in which identical twins share a single placenta. The placenta supplies the developing babies with oxygen, nutrients, and blood flow, but in TTTS, there is an imbalance of blood vessels that interconnect the twins, and thus the vital resources are not evenly distributed. One twin, or the donor twin, shares excess blood with the other, referred to as the recipient twin. This leads to one baby becoming malnourished and possibly anemic, and the other in danger of heart problems due to too much blood.

Nelson described her diagnosis in a heartfelt Instagram video, explaining that she is currently in the pre-stage of TTTS and undergoing frequent monitoring. "I am being scanned twice a week, and each time, things have gotten a little worse," she shared, expressing her fears and hopes for the health of her babies.

Potential Risks of TTTS

If left untreated, TTTS can have devastating consequences. Medical research indicates that:

• 90% of the cases of untreated TTTS lead to loss of one or both twins.
• Despite treatment, only a 70% survival rate for both twins is assured.
• Severe forms can result in preterm labor, cardiac failure in the recipient twin, and organ failure in the donor twin.
• Complications in long-term survivors include neurological damage and developmental delay in surviving infants.

TTTS usually advances in stages, beginning with minimal changes in fluid levels and worsening as one twin continues to get an unequal share of blood. In extreme cases, fetal laser surgery, referred to as the Solomon technique, can be employed to divide the blood vessels and balance the twins.

Why Identical Twin Pregnancies Are More Complicated

Identical twins may develop differently, and their own unique form of placental sharing can have a dramatic effect on pregnancy risk. Jesy Nelson's twins are considered monochorionic diamniotic (mono/di), which means they share a placenta but have two amniotic sacs. This is the type of pregnancy in about 70% of identical twin pregnancies and carries an increased risk of complications like TTTS, umbilical cord entanglement, and growth restriction.

Conversely, dichorionic diamniotic (di/di) twins both have a separate placenta and amniotic sac, which greatly diminishes the threat of TTTS. Twin pregnancy type is normally identified by early ultrasound, with physicians being able to track future complications from inception.

Other Twin Pregnancy Health Risks

Twin pregnancies, even without the presence of TTTS, entail a variety of health risks to the mother as well as infants:

1. Premature Birth

Over 60% of twin pregnancies end in premature delivery, with birth usually taking place before 37 weeks. Premature infants can have immature organs and need neonatal intensive care (NICU) assistance to assist with breathing, feeding, and infection fighting.

2. Gestational Hypertension and Preeclampsia

Pregnant women with multiples are at increased risk of having high blood pressure during pregnancy. This, if left untreated, can result in preeclampsia, a serious complication of pregnancy that can result in damage to organs, preterm labor, and in some cases, maternal or fetal death.

3. Anemia

Pregnant women carrying multiples are twice as likely to experience anemia, a condition where the body does not produce enough healthy red blood cells. This can lead to fatigue, dizziness, and complications during delivery.

4. Birth Defects

According to John Hopkins Medicine, multiple birth babies are twice as likely to have congenital abnormalities compared to single births. These can include heart defects, neural tube defects, and gastrointestinal issues.

5. Amniotic Fluid Imbalances

When twins have to share a placenta, they are more likely to have polyhydramnios (excess amniotic fluid) or oligohydramnios (not enough amniotic fluid). Both result in distress to the babies during fetal development and can result in premature labor.

6. Postpartum Hemorrhage

Twins are at increased risk of excessive postpartum hemorrhage because their uterus is larger and there are greater blood supply needs.

Jesy Nelson's openness about her challenging experience is raising awareness for TTTS, a condition that few individuals—let alone expectant mothers and fathers—might be aware of. Through her tearful video, Nelson stressed the significance of knowing about twin pregnancies aside from the thrill of having multiples. "We had no idea that this type of thing occurs when you're having twins. We just desperately want to make people aware of this because there are so many people who aren't aware."

Her case reminds us of the intricacies involved in twin pregnancy and the significance of early identification and medical management. For mothers carrying twins, frequent ultrasounds and vigilance can become a life-and-death issue for early detection and better outcomes of both babies.

Through constant medical attention and care, she and her partner Zion Foster remain positive and get ready for their babies to be born. In other parents whose situations are no different, the story of Nelson highlights awareness, medical progress, and emotional encouragement in handling complicated pregnancies.

The expecting parents of twin siblings are advised to discuss TTTS screening and possible interventions with their physicians to give their babies the best chance.

A six-year-old girl in China died after receiving an experimental gene-editing treatment for a rare neurodevelopmental disorder. The incident sparked scrutiny on ethics and safety of cutting-edge gene therapies, particularly when they involve children and individualized treatments.

The case, uncovered through a joint investigation by Science and Retraction Watch, sparked international concern as the child's death was never disclosed publicly, despite related preclinical research later being published in Nature.

What Happened?

According to the investigation, the six-year-old girl, identified by the pseudonym "Mei," had Snijders Blok-Campeau syndrome, a rare genetic condition. It caused symptoms like mild intellectual disability and developmental delays.

Her parents reportedly paid more than $800,000 to support development of a personalized ("n=1") gene-editing therapy designed specifically for their daughter's mutation.

In March 2025, she received a spinal infusion containing trillions of adeno-associated viruses (AAVs) carrying a CRISPR-based gene editor intended to correct the faulty gene in brain cells. Within days, she developed a severe immune reaction and died approximately one week after treatment.

An internal hospital review concluded that the most likely cause of death was an overwhelming immune response triggered by the viral delivery system rather than the gene-editing mechanism itself.

The controversy extends well beyond the patient's death. According to Science investigation:

• The child's death was not publicly disclosed.
• The child's treatment was omitted from a later Nature publication describing related preclinical work.
• Animal studies had reportedly shown warning signs, including severe liver and kidney toxicity at high doses.
• The girl's parents may not have been fully informed about the potential side effects of the therapy.

Following the investigation, local Chinese health authorities reportedly fined the hospital involved for faulty execution of the clinical research. Several experts have called for an independent review of the published research and greater transparency around experimental human gene-editing trials.

Also read: Ebola Outbreak in DR Congo Nears 3,000 Cases, 1,300 Deaths as UN Warns Virus Is 'Spreading Like Wildfire'

Bioethicists and gene therapy researchers say the case underscores the need for complete transparency whenever experimental therapies are tested on humans.

Hank Greely, director of the Center for Law and the Biosciences at Stanford University, told Science that the trial "shouldn't have gone to trial".

Pediatrician Marcelo Bellusci, who participates in gene therapy trials, told El País, "In this type of trial there can be serious side effects, but families are always informed about them. This team skipped the current rules."

About Gene-Editing Therapies

Gene-editing technologies such as CRISPR offer the possibility of correcting genetic mutations caused by diseases instead of simply treating symptoms. Several CRISPR-based therapies have shown remarkable success in inherited blood disorders, including sickle cell disease.

However, experts stress that therapies targeting the brain remain considerably more complex because they often require large viral doses and carry greater risks of immune complications.

As more individualized gene-editing therapies move toward human testing, experts argue that every serious adverse event must be reported promptly to regulators, journals, clinicians, and patients to ensure future treatments become both safer and more trustworthy.

Mongolia recently confirmed a suspected case of bubonic plague after a bacteriological laboratory delivered positive results. The National Center for Zoonotic Diseases confirmed on Friday that the case belongs to Mongolia's western Khovd province.

Mongolia Confirms First Human Case Of Bubonic Plague

According to reports, the patient contracted the infection after eating marmot meat during a visit to Ulaankhus soum in neighbouring Bayan-Ulgii province.

Mongolia's first confirmed case of bubonic plague has prompted officials to issue warnings against hunting and eating marmots, a known source of the deadly disease which is also considered a delicacy in the country.

The warnings also stated that individuals must avoid all forms of contact with the rodent, including handling their meat or internal organs. It also said avoid contact with sick or dead rodents as it could significantly increase the risk of infection.

The National Center for Zoonotic Diseases says 17 of Mongolia's 21 provinces are considered high risk regions for plague as the bacterium persists in wildlife.

Also read: What Was The Pseudo-Tuberculosis Like 'Syndrome K' Saved Thousand Lives During World War II?

Why Bubonic Plague Still Lurks In Mongolia?

The Black Death devastated Europe in the 14th century. Even today, a few countries still see cases of plague from time to time.

Humans typically get infected through flea bites from infected rodents, handling and close contact with infected animals and eating undercooked or raw marmot meat, which has been linked to several cases in Mongolia.

Mongolia has reported human plague cases to the World Health Organization since the 1980s. Sporadic infections continue to occur almost every year, particularly in the country's western and northern provinces.

The disease still lives centuries after it was eradicated because it is entrenched in wildlife rather than spreading continuously between people.

Humans are usually infected after being bitten by infected fleas or through hunting, skinning, or eating infected marmots.

Studies show that nearly 60% of Mongolia's reported plague cases since 1998 have been linked to close contact with infected marmots, highlighting why authorities repeatedly warn against hunting and consuming the animals.

Also read: How To Get Rid Of Fleas In Your House And Stop Them From Infecting Your Pets

Several infamous incidents related to the disease have sparked headlines in the last few years.

In 2019, a married couple died after eating raw marmot meat.

In 2020, a teenager also died after eating marmot meat, prompting temporary travel restrictions and heightened surveillance.

The latest confirmed human case in July 2026 follows the same familiar pattern.

Mongolia's challenge is not a new outbreak but an enduring zoonotic disease that resurfaces whenever humans come into contact with infected wildlife.

Where Else Does The Plague Still Exist?

Plague remains endemic in several parts of the world. According to the World Health Organization, the Democratic Republic of Congo, Madagascar, and Peru report the highest number of human cases globally. Since the 1990s, most reported cases have occurred in Africa.

Madagascar experiences seasonal plague almost every year, typically between September and April. The country drew international attention during a major 2017 outbreak, which caused more than 2,500 suspected, probable, and confirmed cases and over 200 deaths.

In the United States, plague is rare but has never disappeared. An average of about seven human cases are reported annually, mostly in rural parts of New Mexico, Arizona, Colorado, California, Oregon, and Nevada.

In 2026, Arizona reported its first human plague case in Apache County in more than a decade.

China has also reported occasional isolated human infections, particularly in Inner Mongolia.

The Ebola outbreak in the Democratic Republic of Congo (DRC) is expanding at an alarming pace, with confirmed infections nearing 3,000 and deaths exceeding 1,300, prompting the United Nations to warn that the virus is "spreading like wildfire" across eastern parts of the country.

The outbreak, caused by the rare Bundibugyo ebolavirus, has become the fastest-growing Ebola epidemic. Unlike Zaire strain, there are currently no approved vaccines or treatments specifically for Bundibugyo Ebola, making containment and management more challenging.

UN Says DRC Outbreak Is Spreading "Like Wildfire"

UN humanitarian officials have described the outbreak as one of the most severe public health emergencies. "The outbreak is spreading like wildfire," UN officials warned recently, highlighting that conflict, population displacement and attacks on healthcare facilities are preventing rapid containment efforts.

The World Health Organization (WHO) has repeatedly warned that the outbreak is becoming increasingly difficult to control.

According to WHO, a bunch of new infections cannot be linked to known transmission chains, indicating that the virus is spreading silently within communities.

Contact tracing remains inadequate to interrupt transmission, while insecurity and misinformation continue to hamper response efforts.

Also read: Ebola Scare In The UK After Humanitarian Worker Monitored In London Hospital; Here's what Happened

Health workers have also demonstrated strikes in some areas over unpaid dues, further disrupting patient care and containment efforts.

WHO has stressed that the global public health risk remains low, as Ebola spreads only through direct contact with the bodily fluids of infected individuals. However, the regional risk remains high because of active movement across borders.

Armed conflict in eastern DRC has limited access to affected communities, while attacks on health facilities, shortages of medical supplies, delayed laboratory testing and public distrust have slowed efforts to isolate patients, trace contacts, and contain the outbreak.

Hope Emerges As First Human Receives Experimental Bundibugyo Ebola Vaccine

Also read: Ebola Outbreak In Congo: UN Warns Frontline Responders As Cases Surface In New Areas

Amid the worsening outbreak, researchers have reached an important scientific milestone in vaccination. The first human volunteer has received an experimental vaccine targeting the Bundibugyo strain of Ebola, marking the world's first Phase I clinical trial.

The study, led by the University of Oxford, will evaluate the vaccine's safety by studying its ability to trigger an immune response in 50 healthy adults.

The vaccine, known as ChAdOx1 BDBV, uses the same viral vector platform that was employed for the Oxford-AstraZeneca COVID-19 vaccine. Professor Katrina Pollock, chief investigator at the Oxford Vaccine Group, described the launch as "an important milestone" in the effort to develop protection against a virus for which no licensed vaccine currently exists.

Africa CDC Director-General Dr Jean Kaseya also welcomed the development, noting that although early-stage trials will not immediately help affected communities battle the current outbreak, they are critical for building better tools against future epidemics.

WHO notes that currently approved Ebola vaccines, including Ervebo, are designed to protect against the Zaire ebolavirus, not the Bundibugyo strain responsible for the ongoing outbreak. Researchers are also in the process to determine whether existing vaccines may offer partial cross-protection while Bundibugyo-specific vaccines continue to be developed.

Alongside vaccine research, WHO and international partners have launched clinical trials in the DRC to evaluate experimental therapies, including the monoclonal antibody MBP134 and antiviral drug remdesivir, in patients infected with the Bundibugyo virus. Researchers hope these studies will identify effective treatment options for future outbreaks.